Tower Bridge Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
10,645
+3,675
+53% +$497K 0.15% 106
2026
Q1
$890K Buy
+6,970
New +$870K 0.09% 129

Other funds holding XBI

Tower Bridge Advisors's XBI Position: Q2 2026 in Review

Tower Bridge Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 53% in Q2 2026, buying an estimated $497K and bringing the position to 10,645 shares worth $1.68M. The position accounts for 0.15% of the portfolio, ranked #106.

Tower Bridge Advisors first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Tower Bridge Advisors held 10,645 shares of State Street SPDR S&P Biotech ETF worth $1.68M as of Q2 2026.
  • Tower Bridge Advisors bought 3,675 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $497K.
  • State Street SPDR S&P Biotech ETF made up 0.15% of Tower Bridge Advisors's portfolio in Q2 2026, its #106 holding.
  • Tower Bridge Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Tower Bridge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.